https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-02-10 / J Med Case Rep 2024 Feb;18(1):88
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-02-10 / J Med Case Rep 2024 Feb;18(1):882024-02-10 00:00:002024-02-10 00:00:00Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-02-03 / Neurol Sci 2024 Jun;45(6):2561-2578
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-02-03 / Neurol Sci 2024 Jun;45(6):2561-25782024-02-03 00:00:002024-02-03 00:00:00A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-01-05 / EBioMedicine 2024 Jan;100:104963
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-01-05 / EBioMedicine 2024 Jan;100:1049632024-01-05 00:00:002024-01-05 00:00:00Glioblastoma vaccines: past, present, and opportunities
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-12-26 / Mol Aspects Med 2024 Feb;95:101239
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-12-26 / Mol Aspects Med 2024 Feb;95:1012392023-12-26 00:00:002024-01-30 12:49:47Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-12-13 / Immunol Rev 2024 Jan;321(1):350-370
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-12-13 / Immunol Rev 2024 Jan;321(1):350-3702023-12-13 00:00:002023-12-13 00:00:00Decoding immunogenic cell death from a dendritic cell perspective
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-11-14 / Trends Cancer 2024 Jan;10(1):8-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-11-14 / Trends Cancer 2024 Jan;10(1):8-112023-11-14 00:00:002023-11-14 00:00:00Targeting immunogenic cell death for glioma immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-11-12 / Med Oncol 2023 Nov;40(12):354
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-11-12 / Med Oncol 2023 Nov;40(12):3542023-11-12 00:00:002023-11-12 00:00:00Therapeutic cell-based vaccines for glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-11-06 / Cureus 2023 Nov;15(11):e48412
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-11-06 / Cureus 2023 Nov;15(11):e484122023-11-06 00:00:002023-11-06 00:00:00Radioimmunotherapy With WT1 Dendritic Cell Vaccine for End-Stage Lung Adenocarcinoma Markedly Shrinks Tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-11-01 / Immun Inflamm Dis 2023 Nov;11(11):e1099
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-11-01 / Immun Inflamm Dis 2023 Nov;11(11):e10992023-11-01 00:00:002025-09-04 17:02:01The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-10-19 / Methods Cell Biol 2024;183:51-113
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-10-19 / Methods Cell Biol 2024;183:51-1132023-10-19 00:00:002024-04-20 10:47:17Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
